NYSE · Health care

Oragenics Inc (OGEN)

It posted a net loss of $10.1M. At June 30, 2026 it held $3.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$0.49

-3.02% on the day · September 25, 2026

52-week range $0.48 to $1.45

Market cap

$2.2M

What Oragenics Inc does

Oragenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGEN.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$9.4M	-$9.8M	-$4.56	n/a
2024	n/a	-$10.6M	-$10.6M	-$47.88	n/a
2023	$37.7K	-$20.9M	-$20.7M	-$274.71	n/a
2022	$131.5K	-$14.4M	-$14.3M	-$212.77	-$15.4M
2021	$87K	-$15.8M	-$15.7M	-$4.19	-$13.5M
2020	n/a	-$26.6M	-$26.4M	-$14.06	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 6, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 7, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Oragenics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 16, 2026
Investor disclosure 8-K
August 28, 2026
Stock exchange listing notice 8-K
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.57 versus -$3.10.
July 6, 2026
Executive or director change 8-K
May 20, 2026
Additional proxy material DEFA14A
May 20, 2026
Proxy statement DEF 14A
May 19, 2026
Investor disclosure 8-K
May 8, 2026
Preliminary proxy statement PRE 14A
May 8, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.51 versus -$3.65.
May 7, 2026
Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 7, 2026. Insider transactions on SEC

Insider trades

What the people running Oragenics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about OGEN

What does Oragenics Inc do?

Oragenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGEN.

Is Oragenics Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.1M.

When did Oragenics Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 16, 2026.

Similar companies

Compare OGEN with

Compare OGEN with any company

Follow OGEN

Get an email when Oragenics Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow OGEN: get an email when it files

Where the numbers come from

Financial figures are the values Oragenics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.